Participants 80 104 5
relapsed Hodgkin disease
Participants 167 286 3
granulocyte macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed or refractory Hodgkin disease.
Participants 393 524 6
Twenty-four patients (twelve of whom were controls) treated with high-dose chemotherapy and autologous bone marrow transplantation.
Participants 1794 1869 3
patients with relapsed Hodgkin disease who received intensive chemotherapy.
